CN116712361A - 列当提取物在制备改善皮肤弹性和皱纹组合物中的应用 - Google Patents
列当提取物在制备改善皮肤弹性和皱纹组合物中的应用 Download PDFInfo
- Publication number
- CN116712361A CN116712361A CN202310702529.7A CN202310702529A CN116712361A CN 116712361 A CN116712361 A CN 116712361A CN 202310702529 A CN202310702529 A CN 202310702529A CN 116712361 A CN116712361 A CN 116712361A
- Authority
- CN
- China
- Prior art keywords
- extract
- broomrape
- wrinkles
- composition
- skin elasticity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 87
- 241000336315 Cistanche salsa Species 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 230000037303 wrinkles Effects 0.000 title claims abstract description 34
- 230000037394 skin elasticity Effects 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims description 10
- 230000000694 effects Effects 0.000 claims abstract description 26
- 230000002500 effect on skin Effects 0.000 claims abstract description 22
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 22
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims abstract description 21
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims abstract description 21
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 11
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 11
- 102000043136 MAP kinase family Human genes 0.000 claims abstract description 8
- 108091054455 MAP kinase family Proteins 0.000 claims abstract description 8
- 102100034404 Nuclear factor of activated T-cells, cytoplasmic 1 Human genes 0.000 claims abstract description 7
- 101710151542 Nuclear factor of activated T-cells, cytoplasmic 1 Proteins 0.000 claims abstract description 7
- 230000028327 secretion Effects 0.000 claims abstract description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 22
- 239000002537 cosmetic Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 12
- 102000012422 Collagen Type I Human genes 0.000 claims description 7
- 108010022452 Collagen Type I Proteins 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 108010018242 Transcription Factor AP-1 Proteins 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 2
- 102100020847 Protein FosB Human genes 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 abstract description 10
- 230000005764 inhibitory process Effects 0.000 abstract description 9
- 230000034994 death Effects 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 235000013305 food Nutrition 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- 239000003642 reactive oxygen metabolite Substances 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- -1 AP-1 Proteins 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 206010051246 Photodermatosis Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 235000013376 functional food Nutrition 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000008845 photoaging Effects 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 6
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 6
- 241001508464 Orobanche Species 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 244000130270 Fagopyrum tataricum Species 0.000 description 4
- 235000014693 Fagopyrum tataricum Nutrition 0.000 description 4
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 4
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 4
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 4
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930185474 acteoside Natural products 0.000 description 4
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 description 4
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100023132 Transcription factor Jun Human genes 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- UBORTCNDUKBEOP-UHFFFAOYSA-N L-xanthosine Natural products OC1C(O)C(CO)OC1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- UBORTCNDUKBEOP-HAVMAKPUSA-N Xanthosine Natural products O[C@@H]1[C@H](O)[C@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-HAVMAKPUSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- UBORTCNDUKBEOP-UUOKFMHZSA-N xanthosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UUOKFMHZSA-N 0.000 description 2
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- FNMHEHXNBNCPCI-QEOJJFGVSA-N Isoacteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O[C@H](COC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H]1O FNMHEHXNBNCPCI-QEOJJFGVSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical class CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002729 effect on secretion Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- 235000008718 isoliquiritigenin Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940069825 okra extract Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 239000001331 rosmarinus officinalis leaf Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biochemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了列当提取物在制备改善皮肤弹性和皱纹组合物中的应用。本发明所述的列当提取物具有优异的抗氧化效果,优异的ROS抑制活性,同时还能够抑制紫外线引起的真皮纤维芽细胞死亡、抑制MMP‑1的分泌和MAPKs、MMPs及NFATc1的表达。
Description
技术领域
本发明属于中药新用途领域,尤其是涉及列当提取物在制备改善皮肤弹性和皱纹组合物中的应用。
背景技术
随着现代人的生活水平的提高和老龄人口的增加,对防止老化、改善皱纹、美白、防晒等相关功能性化妆品的关注和需求正在增加。由于基础化妆品或功能性化妆品的原料基本为化学物质,所以化妆品对人体的安全性问题越来越受到关注。因此含有天然原料及有机原料的产品越来越受到消费者的青睐,相关产品的市场规模也在增加。
光老化是皮肤老化的主要原因。有数据表明,光老化占可视性皮肤老化现象90%以上。紫外线大致分为UVA、UVB及UVC。其中主要对老化产生影响的UVB(290~320nm)可以透过表皮层,促进黑素细胞生产黑色素,形成粗皱纹。UVA(320~400nm)可以透过真皮层,被认为是光老化的主要原因。可见UVA、UVB对光老化都有很大的影响,因此阻断这两个范围内的紫外线非常重要。
其中UVB对人体皮肤损伤影响最容易、最快,通过皮肤干燥及皮肤红斑、色素沉着、表皮肥厚等现象和氧化应激及抗氧化机制的不均衡诱发,损伤构成皮肤的脂质、蛋白质和酶等,加深炎症反应和皮肤癌及光老化,导致皮肤损伤。通过UVB暴露诱导生成的活性氧是光老化原因之一,通过刺激细胞内的信号传达体系,对DNA和脂质及蛋白质等生物分子诱发氧化应激,导致皮肤组织损伤。
另外,表皮角质细胞和真皮纤维芽细胞在活性氧的刺激下,激活活化蛋白-1(AP-1)及核因子-κB(NF-κB)的转录因子,分泌与炎症相关的细胞因子,增加基质金属蛋白酶(MMPs)的分泌,使构成皮肤组织的胶质和弹性纤维发生分解,减少皮肤弹性,促进皱纹生成。
随着人们对皮肤光老化导致的改善皮肤组织损伤及皱纹中的抗氧化物质的关注以及追求没有副作用的物质,天然原料以及应用天然原料的功能性产品的开发正在蓬勃发展。
列当是寄生在菊科艾属的植物根部的草本植物,主要分布在我国东北部、内蒙古等地区。列当具有润肠、止血等功效,主要用于治疗肠炎、膀胱炎、子宫出血等。研究表明,列当含有D-甘露醇、β-谷甾醇、琥珀酸、咖啡酸、原儿茶醛及胡萝卜苷等,但到目前为止还没有研究证明列当具有改善皮肤弹力及皱纹的效果。
发明内容
有鉴于此,本发明旨在克服现有技术中的缺陷,提出列当提取物在制备改善皮肤弹性和皱纹组合物中的应用。
为达到上述目的,本发明的技术方案是这样实现的:
作为本发明的第一个目的,是提供了列当提取物在制备改善皮肤弹性和皱纹组合物中的应用。
优选地,所述组合物通过抑制真皮纤维芽细胞的ROS达到改善皮肤弹性和皱纹的效果。
优选地,所述组合物通过抑制真皮纤维芽细胞的MAPKs、AP-1、MMPs及NFATc1蛋白质的分泌达到改善皮肤弹性和皱纹的效果。
优选地,所述组合物通过抑制MMP-1蛋白质和促进Ⅰ型胶原蛋白质的表达达到改善皮肤弹性和皱纹的效果。
作为本发明的第二个目的,是提供了一种改善皮肤弹性和皱纹的化妆品组合物,所述化妆品组合物的有效成分包含列当提取物。
作为本发明的第三个目的,是提供了一种改善皮肤弹性和皱纹的药品组合物,所述药品组合物的有效成分包含列当提取物。
本发明对列当提取物成分的有用性进行了研究,结果发现列当提取物自由溶解活性效果突出,抑制ROS活性优异,不仅抑制了紫外线引起的真皮纤维芽细胞的死亡,还对AP-1、MMP-1的分泌以及MAPKs、MMPs及NFATc1的表达均具有抑制效果。
在本发明的优选实施例子中,确认了列当提取物含有麦角甾苷、异麦角甾苷、黄药苷及2'-乙酰乙酰甲苷。
在本发明中使用的术语,“提取物”包括通过列当的提取处理获得的提取液、上述提取液的稀释液或浓缩液、通过干燥上述提取液获得的干燥物、上述提取液的精制物或上述提取液、稀释液、浓缩液、干燥物的混合物等,提取液本身及利用提取液形成的所有剂型的提取物均在本发明所述的“提取物”范围之内。
在上述苦荞的提取物的提取方法并不特别受限制,可根据本领域常用方法提取,包括但不限于热水提取法、超声波提取法、过滤法、环流提取法等,它们可以单独使用或同时将两种以上提取方法合并使用。
在本发明中,用于提取上述列当的提取溶剂的种类没有特别限制,可以使用相应技术领域公告的任意溶剂。上述提取溶剂包括但不限于水、甲醇、乙醇、丙醇等C1至C4的低级醇。甘油、丁二醇、丙二醇等多元醇;以及甲基醋酸酯、乙基醋酸酯、丙酮、苯、己烷、二乙醚、二氯甲烷等碳氢化合物溶剂;或者可以使用它们的混合物,值得一提的是,可单独使用水、低级醇、1,3-丁二醇、乙酸乙酯或两种以上的混合物。
在本发明中,热水提取或冷浸提取的提取物过滤以去除固体颗粒,例如利用尼龙等过滤,或者利用冷冻过滤法等过滤后,可以直接使用或者利用冻结干燥、热风干燥、喷雾干燥等干燥后使用。
在发明中,上述列当的提取物可以从列当的全草、叶子、茎、根及果实中的任何一个以上部位提取。另外,上述列当提取物可以从天然、杂交或变种植物中提取,也可以从植物组织培养物中提取。
在本发明中,上述列当提取物的特点是列当提取物中含有麦角甾苷、异麦角甾苷、黄药苷及2'-乙酰乙酰甲苷。
本发明实验结果显示,上述列当提取物的特点为其本身呈现出改善皮肤弹性和皱纹的活性。
在本发明的实施例中,验证了上述列当提取物具有优异的自由基消除活性效果、优异的ROS抑制活性、抑制紫外线引起的真皮纤维芽细胞死亡、AP-1和MMP-1的分泌和抑制MPAKs、MMPs及NFA Tc1的表达的活性。
本发明的列当提取物以具有抗氧化活性为特征。在本发明的实施例中可以观察到,与阴性对照组相比,处理了列当提取物的实验组整体上具有优秀的抗氧化效果。据分析,这些抗氧化效果数值与阳性对照组维生素C处理组相比也相似。
另外,列当用提取物在真皮纤维芽细胞内也能确认对氧化压力具有优异的细胞保护效果。
另外,本发明的列当提取物的特征是优异的ROS抑制活性。在本发明的实施例中得出,与MMP-1抑制活性对照组相比,可以确认ROS抑制活性多减少21.2%。
另外,本发明的列当提取物的特点是抑制MAPKs的磷酸化。在本发明的实施例中,与AP-1、MMP-1及NFATc1的抑制活性对照组相比,可以发现磷酸化减少。
另一方面本发明提供了一种包括列当提取物作为有效成分的改善皮肤弹性和皱纹的药学组合物。本发明的药学组合物具有优异的ROS抑制能力。另外,由于MPAKs、MMP-1和NFATc1的抑制表现活性优异,因此可以有效地用作于改善皮肤弹力及皱纹相关的药学组合物。
在本发明的改善皮肤弹性和皱纹的化妆品组合物中,上述化妆品的剂型选择包括但不限于溶液、外用软膏、面霜、洗面奶、化妆水、柔肤水、面膜、乳液、隔离霜、精华、香皂、液体清洁剂、沐浴露、防晒霜、防晒精油、乳浊液、凝胶、乳液、香皂、含有粉末清洁剂、精油、粉末粉底、液体粉底、膏状粉底及喷雾等。
另外,本发明的改善皮肤弹力及皱纹化妆品组合物可添加一种以上与一般皮肤化妆品相配套的化妆品学上允许的辅料,通常的成分可以包括适当调配油分、水、表面活性剂、保湿剂、低级酒精、增稠剂、分散剂、色素、防腐剂、香料等,但不限于此。
在本发明的改善皮肤弹力及皱纹化妆品组合物中,化妆品学上允许的辅料根据剂型进行选择,例如:
当本发明的剂型为软膏、糊剂、面霜或凝胶时,可以使用动物油、植物油、蜡、石蜡、淀粉、三聚氰胺、纤维素衍生物、聚乙烯醇、硅、二氧化硅、滑石粉、氧化锌或它们的混合物作为辅料成分。
当本发明的剂型为粉末或喷雾时,可以使用乳糖、滑石、二氧化硅、聚酰胺粉末或它们的混合物作为辅料成分,特别是喷雾时,可以追加包含丙烷、丁烷或二甲醚等推进剂。
当本发明的剂型为溶液或乳浊液时,溶剂、溶解剂或乳浊剂被用作辅料成分,例如可以使用水、乙醇、异丙醇、乙基碳酸酯、丙二醇、1-3-丁二醇等。特别是可以使用棉花籽油、花生油、玉米油、橄榄油、芝麻油或聚乙烯醇。
当本发明的剂型为悬浮液时,辅料成分可以包括如水、乙醇或丙二醇等液体的稀释剂,也可包括卡波树脂等悬浮剂、微晶性纤维素等。
当本发明的剂型为肥皂时,辅料成分可以使用脂肪酸的碱金属盐、二硝酸酯、亚麻酸衍生物、脂肪醇、植物油、甘油和糖等作为辅料成分。
本发明还可提供含有列当提取物作为有效成分的改善皮肤弹性及皱纹的食品。其效果如上文所述。上述食品可以作为健康功能食品使用。上述食品除有效成分外,还可包含食品学上允许的食品辅助添加剂。
在本发明中“食品辅助添加剂”是指可以辅助添加到食品中的成分,根据食品的剂型可选择适当的成分添加其中。食品辅助添加剂包括多种营养剂、维生素、矿物质、合成风味剂及天然风味剂等风味剂、着色剂、二甲酸及其盐、有机酸、增稠剂、pH调节剂、稳定剂、防腐剂、甘油、酒精、碳酸饮料中使用的碳酸化剂等。上述例子并不限制本发明的食品辅助添加剂的种类。
本发明的产品可以包括健康功能食品。在本发明中,“健康功能性食品”是指使用对人体有用的功能性原料或成分以胶囊、粉末、颗粒、液体及丸等形态制造及加工的食品。这里的“功能性”是指对人体具有营养学或生理学的作用。本发明的健康功能性食品可以采用此行业通用的方法制备,在制备过程中,可以添加本行业常规添加的原料和成分。
另外,上述健康功能性食品与普通药品不同,具有以食品为原料、长期服用药品时不会产生副作用等优点。本发明的健康功能性食品还可以作为提高皮肤保湿效果的辅助食品食用。
本发明的健康功能性食品可以添加其他的辅料或已知的添加剂制成各种类型的食品,如肉类、香肠、面包、巧克力、糖果、零食、饼干、披萨、方便面类、口香糖、冰淇淋、调料、饮料、茶、运动饮料、酒类及维生素复合剂等,还可以将苦荞提取物为有效成分添加至茶、果冻及果汁等中。
在本发明的医药用品组合物中,除了上述列当提取物外,根据需要还可以包括药学上允许的辅料。所述辅料可以为填充剂、增稠剂、结合剂、湿润剂、硼解剂、表面活性剂、润滑剂、甜味剂、芳香剂、防腐剂等。
所述药学上可允许的辅料可选范围如下:乳糖、葡萄糖、松脂醇、木糖醇、麦芽糖醇、淀粉、明胶、甘油、洋槐胶、纤维素、甲基纤维素、聚乙烯吡咯酮、水、甲基羟苯甲酸酯、丙基羟苯甲酸酯、滑石、矿物油、丙二醇、聚乙二醇、植物油、可注射的酯、吐温61、可可脂、等。
另外,当将本发明的苦荞提取物用作医药用品时,还可附加一种以上具有相同或类似功能的有效成分。例如可以包含目前公知的改善皮肤弹性及皱纹的成分。当包括额外的过敏性免疫调节成分时,本发明的组合物的效果会进一步增加,如菊花提取物、迷迭香叶提取物、秋葵提取物、人参提取物、苦参提取物、木瓜叶提取物、向日葵提取物等组成的组选择一种或两种以上的成分。添加上述有效成分时,需要考虑复合使用后皮肤安全性以及有效成分的稳定性等问题。上述医药外品组合物是公知的改善皮肤皱纹成分,附加的有效成分的添加量为整个组合物的重量0.001%~10%,上述含量范围可根据皮肤安全性和苦荞提取物剂型化时的难易程度等条件进行调节。
本发明的医药外品组合物可以包括但不限于消毒清洁剂、淋浴泡沫、软膏液、湿巾、涂层剂等。医药外用品的制备方法、使用方法等可以从该技术领域已知的常规技术手段中适当选择。
相对于现有技术,本发明具有以下优势:
(1)本发明所述的列当提取物具有优异的抗氧化效果,ROS抑制活性优异,同时还能够抑制紫外线引起的真皮纤维芽细胞死亡、抑MMP-1、MAPKs、MMPs及NFATc1的表达。
(2)本发明改善皮肤弹性及皱纹组合物以天然植物提取物列当提取物为原料,不仅对人体非常安全,而且非常稳定,在化妆品及医药品领域都可以有效利用。
附图说明
图1为本发明实施例2的列当提取物的色谱图;
图2为本发明实验例1的细胞存活率统计图;
图3为本发明实验例2的DPPH清除率的结果图
图4为本发明实验例3的ROS生成量统计图;
图5为本发明实验例4的MMP-1生成量统计图;
图6为本发明实验例5-1的ERK、p38及JNK蛋白质免疫印迹结果;
图7为本发明实验例5-1的c-Jun及c-FOS蛋白质免疫印迹结果和生成量统计图;
图8为本发明实验例5-2的MMP-1和I型胶原蛋白免疫印迹结果和生成量统计图;
图9为本发明实验例5-3的NFATc1蛋白质免疫印迹结果和生成量统计图。
具体实施方式
除有定义外,以下实施例中所用的技术术语具有与本发明创造所属领域技术人员普遍理解的相同含义。以下实施例中所用的试验试剂,如无特殊说明,均为常规生化试剂;所述实验方法,如无特殊说明,均为常规方法。
下面结合实施例来详细说明本发明创造。
实施例1.列当提取物的制备
1-1.列当提取物的制备
用流水清洗列当,去除杂质后,取列当100g,加70%乙醇溶液500ml,在室温下搅拌提取2天。上述过程重复进行三次。收集获得的提取液后,在40℃以下减压浓缩、干燥,制成粉末形态,得率为26.5%。
实施例2.列当提取物的成分分析
使用高速液体色谱仪Thermo UHPLC U3000分析实施例1中制备的列当提取物的指标成分的含量。
HPLC分析条件如下:色谱柱使用了Sunfire C18 column(Water s,250×4.6mm,5μm),色谱柱温度为30℃,UV波长在280nm处测定,移动相采用含0.1%甲酸的水和亚硝基(梯度模式)。上述实施例1中制备的列当提取物以1mg/mL的浓度溶解在移动溶剂中,注入10μL后测定流速为1mL/min。上述提取物的指标成分含量如下表所示。
表1列当提取物的成分分析
参照上述表1及图1可知,列当含有大量麦角甾苷(Acteoside)、异麦角甾苷(Isoacteoside)、黄药苷(Crenatoside)及2'-乙酰毛蕊花糖苷(2'-acetylacetoside)。
实验例1.列当提取物的细胞毒性
确认了上述实施例1中制造的用于列当的提取物的真皮纤维芽细胞的细胞毒性。具体来说,
使用了含有10%牛胎儿血清的DMEM培养基,在37℃、5%CO 2条件的培养基中培养了真皮纤维芽细胞。将细胞培养用96孔板培养到汇合状态后,将实施例1制备的列当提取物分别以1μg/mL、10μg/mL和100μg/mL浓度处理,48小时后,用MTT处理,再培养2个小时。培养后去除所有培养液,溶解DMSO 100μL快速溶解生成的福尔马赞后,用微孔板阅读器测定570nm和690nm处波长的吸光度。
结果如图2所示,可以看出本发明的列当提取物在所有浓度中细胞存活率都在95%以上,不显示细胞毒性。
实验例2.列当提取物的抗氧化活性
将实施例1中准备的列当提取物分别以1μg/mL、10μg/mL、50μg/mL、100μg/mL、250μg/mL浓度放入96孔板中,在37℃下培养30分钟,利用光谱仪测定还原的DPPH量在520nm处的吸光度,与不施加样本的无添加对照组进行了活性比较。为了进行比较实验,使用了维生素c作为阳性对照组。上述试验重复3次,其结果如图3所示。
由图3可以看出,与阴性对照组相比,处理了列当提取物的实验组整体上具有非常优异的抗氧化效果,这些抗氧化效果数值与阳性对照组维生素C处理相比也接近,具有非常优异的抗氧化活性。
实验例3.列当提取物细胞内的ROS活性
为了测定真皮纤维芽细胞的ROS生成量,将真皮纤维芽细胞接种到含10%的牛胎儿血清、1%青霉素在内的DMEM培养基上,在37℃、5%CO2条件下培养24~48小时,用于实验。
将真皮纤维芽细胞分别以1.2×105至106浓度注入,将本发明的列当提取物(实施例1)配制为1μg/mL、10μg/mL及100μg/mL的浓度,培养48小时。作为阳性对照组。培养后,利用灭菌的PBS(pH7.4)清洗2次后,用DCFDAFL-2将细胞染色30分钟后,用冰冷的PBS清洗2次。放入0.05%的TE将细胞剥离后,用冰冷的PBS将细胞收集起来,转移到离心管。通过离心机沉淀细胞,去除上层液,用冰冷的PBS释放细胞后装入管子里,在冰箱中保持冰冷。用FACs测定ROS。
结果如图4所示,可以看出在本发明的列当提取物中,真皮纤维芽细胞内的ROS生成以浓度依赖性消失。特别是,在100μg/ml的浓度下,真皮纤维芽细胞内的自由基的生成减少了28.86%,通过上述结果可以确认本发明的列当提取物在真皮内对氧化压力也表现出优异的细胞保护效果。
实验例4.列当提取物的MMP-1(ELISA)抑制活性
为了确认通过抑制MMP-1、(MMP-1,matrix metalloproteinase-1)带来的改善皮肤皱纹,验证了上述实施例1中制备的列当提取物(实施例1)对MMP-1活性抑制的影响。
具体来说,将本发明的列当提取物分别用作1μg/mL、10μg/mL和100μg/mL的浓度。实验进行前一天,利用捕获抗体涂层96孔板。24小时后,用水洗缓冲器将涂层板进行清洗。利用试剂稀释剂进行1小时的调节。用洗涤缓冲液对板进行清洗。放入样品和标准,等待2小时。用洗涤缓冲液对板进行清洗。之后放入检测抗体,等待2个小时。用洗涤缓冲液对板进行清洗,放入链霉亲和素,在黑暗处等待20分钟。用洗涤缓冲液对板进行清洗,放入基质溶液,在黑暗处等待20分钟。最后放入停止溶液轻轻摇晃后,用ELISA仪器测定在450nm处MMP-1活性抑制能力。
结果如图5所示,可以看出与MMP-1抑制活性控制组相比,本发明的列当提取物分别抑制了39.45%和10.56%。通过上述实验结果,可以确认本发明的列当提取物可以用作改善皮肤弹性和皱纹的活性成分。
实验例5.列当提取物在真皮纤维芽细胞内的蛋白质表现
5-1MAPKs蛋白质磷酸化
为了评估在UVB照射的真皮纤维芽细胞中使用列当提取物处理所引起的磷酸化程度,对MAPKs蛋白质进行了蛋白印记分析。
结果如图6所示,可以看出AP-1蛋白质可以调节与细胞生长和分化相关的众多基因的出现,并调节部分MMPs的表达。
本实验例还通过蛋白印记分析方法确认UVB照射的真皮纤维芽细胞中AP-1的构成因子c-Jun及c-FOS蛋白质的磷酸化抑制情况。
结果如图7所示,可以看出UVB照射诱导了AP-1的构成因子c-Jun及c-FOS蛋白质的磷酸化,由此确认了AP-1蛋白质的活性增加。相反,在使用本发明的列当提取物的试验组中,可以发现随着浓度升高对c-Jun及c-FOS蛋白质的磷酸化抑制作用越强。
通过上述结果,可以确认本发明的列当提取物抑制了c-Jun及c-FOS蛋白质的磷酸化,从而阻碍了转录因子AP-1蛋白质的活性,最终抑制了MMPs酶的出现。
5-2.MMP-1和Ⅰ型胶原蛋白质磷酸化
I型胶原蛋白通过暴露在UV下而显著分解,从而生成皮肤皱纹。因此,通过蛋白印记分析法确认了UVB照射的真皮纤维芽细胞中,随着列当提取物的处理,MMP-1蛋白质及Ⅰ型胶原蛋白质的变化。
结果如图8所示,可以看出以通过UVB照射增加的MMP-1蛋白质的表达增加因本发明的列当提取物的处理而浓度依赖性减少。另外,通过UVB照射减少的Ⅰ型胶原蛋白质可以随着列当提取物浓度的增加而增加。
5-3.NFATc1蛋白质磷酸化
为了确认本发明的列当提取物的细胞内基质组份,通过蛋白印记分析方法确认了UVB照射的真皮纤维芽细胞中AP-1的构成因子NF ATc1蛋白质的磷酸化抑制。
结果如图9所示,可以看出UVB照射诱导了NFATc1蛋白质的磷酸化,增加了活性。相反,在处理本发明的列当提取物的试验组中,可以发现随着列当提取物浓度的增加对NFATc1蛋白质的磷酸化抑制作用增强。
通过上述结果,可以确认本发明的列当提取物抑制了MAPKs蛋白质的磷酸化,从而阻碍了转录因子AP-1蛋白质的活性,抑制了MMPs酶的显现及NFATc1蛋白质的出现。
以上所述仅为本发明创造的较佳实施例而已,并不用以限制本发明创造,凡在本发明创造的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明创造的保护范围之内。
Claims (7)
1.列当提取物在制备改善皮肤弹性和皱纹组合物中的应用。
2.根据权利要求1所述的应用,其特征在于:所述组合物通过抑制真皮纤维芽细胞的ROS达到改善皮肤弹性和皱纹的效果。
3.根据权利要求1所述的应用,其特征在于:所述组合物通过抑制真皮纤维芽细胞的MAPKs、AP-1、MMPs及NFATc1的分泌达到改善皮肤弹性和皱纹的效果。
4.根据权利要求1所述的应用,其特征在于:所述组合物通过抑制MMP-1蛋白质和促进Ⅰ型胶原蛋白质的表达达到改善皮肤弹性和皱纹的效果。
5.一种改善肌肤弹性和皱纹组合物,其特征在于:所述组合物中的有效成分包含列当提取物。
6.一种改善皮肤弹性和皱纹的化妆品组合物,其特征在于:所述化妆品组合物的有效成分包含列当提取物。
7.一种改善皮肤弹性和皱纹的药品组合物,其特征在于:所述药品组合物的有效成分包含列当提取物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310702529.7A CN116712361A (zh) | 2023-06-14 | 2023-06-14 | 列当提取物在制备改善皮肤弹性和皱纹组合物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310702529.7A CN116712361A (zh) | 2023-06-14 | 2023-06-14 | 列当提取物在制备改善皮肤弹性和皱纹组合物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116712361A true CN116712361A (zh) | 2023-09-08 |
Family
ID=87871162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310702529.7A Pending CN116712361A (zh) | 2023-06-14 | 2023-06-14 | 列当提取物在制备改善皮肤弹性和皱纹组合物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116712361A (zh) |
-
2023
- 2023-06-14 CN CN202310702529.7A patent/CN116712361A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11026441B2 (en) | Avocado flesh and/or skin extract rich in polyphenols and cosmetic, dermatological and nutraceutical compositions comprising same | |
US10688142B2 (en) | Methods of treatment using a lipid extract of Passiflora seeds concentrated in its unsaponifiable fraction | |
KR101387308B1 (ko) | 황칠나무 발효산물을 이용한 피부 미백 화장료 조성물 | |
CN111053716A (zh) | 一种茯茶提取物在制备皮肤调节产品中的用途 | |
KR20170025375A (ko) | 피부 개선용 조성물 | |
WO2006069072A2 (en) | Method and composition for reducing the appearance of wrinkles | |
KR20170037570A (ko) | 들깻잎 추출물을 함유하는 피부노화 방지 및 주름 개선용 조성물 | |
KR20170137412A (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR102577528B1 (ko) | 피부 개선용 조성물 | |
KR20140089305A (ko) | 참가시나무 추출물를 활성성분으로서 포함하는 피부 미백 또는 주름개선용 조성물 | |
KR20210134284A (ko) | 분갈 추출물 또는 이로부터 유래된 화합물을 포함하는 피부 개선용 조성물 | |
KR102244585B1 (ko) | 피부 노화 개선 복합 화장료 조성물 | |
CN116712361A (zh) | 列当提取物在制备改善皮肤弹性和皱纹组合物中的应用 | |
KR20170136919A (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR20170025355A (ko) | 피부 개선용 조성물 | |
KR20170025352A (ko) | 피부 개선용 조성물 | |
KR101069906B1 (ko) | 비짜루국화 추출물을 함유하는 피부 상태개선용 조성물 | |
KR20160003916A (ko) | 한약재 추출물을 포함하는 미백 또는 안색 개선용 화장료 조성물 | |
KR102286969B1 (ko) | 정제어유 유래 오메가-7 및 홍삼을 포함하는 피부 상태 개선용 조성물 | |
KR102472093B1 (ko) | 피부 개선용 조성물 | |
KR20170025364A (ko) | 피부 개선용 조성물 | |
CN116650378A (zh) | 苦荞提取物在制备改善肌肤弹性和皱纹产品中的应用 | |
KR102573377B1 (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR102152932B1 (ko) | 카테킨 배당체를 유효 성분으로 함유하는 피부 상태 개선용 조성물 및 이를 이용한 피부 상태 개선 방법 | |
JP2024049127A (ja) | 肌のくすみ改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |